BC Extra | May 6, 2019
Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a...
BC Innovations | Apr 18, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting MGLL could help treat chemotherapy-induced neuropathic pain. In a mouse model of paclitaxel-induced neuropathic pain, two tool compound MGLL inhibitors decreased mechanical allodynia compared with vehicle. Next steps could...
BC Week In Review | Mar 30, 2018
Company News

Celgene licenses preclinical candidate from Abide

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
BC Extra | Mar 28, 2018
Company News

Celgene, Abide reshuffle partnership

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
BC Week In Review | Oct 20, 2017
Clinical News

Abide begins Phase Ib trial for neuroinflammatory pain candidate ABX-1431

Abide Therapeutics Inc. (San Diego, Calif.) began a crossover Phase Ib trial of ABX-1431 to treat neuroinflammatory disorders associated with central pain. ABX-1431 is a small molecule inhibitor of monoglyceride lipase (MGLL; MAGL), which regulates...
BC Week In Review | Oct 3, 2016
Company News

Abide Therapeutics, Celgene deal

Celgene exercised an option from a 2014 deal and will obtain worldwide rights outside the U.S. to Abide’s ABX-1431 . The product is in Phase Ia testing, and Abide plans to conduct additional Phase Ib trials...
BC Extra | Sep 29, 2016
Company News

Celgene opts in for ex-U.S. rights to Abide compound

Celgene Corp. (NASDAQ:CELG) exercised an option giving it ex-U.S. rights to ABX-1431 from Abide Therapeutics Inc. (San Diego, Calif.). The small molecule inhibitor of monoacylglycerol lipase ( MAGL ) is in Phase I testing for neurological diseases....
BC Innovations | Feb 4, 2016
Distillery Therapeutics

Therapeutics: Monoacylglycerol lipase (MAGL)

Neurology INDICATION: Pain Mouse studies suggest combining MAGL inhibitors with morphine could help treat neuropathic pain while limiting the development of morphine tolerance. In a mouse model of injury-induced neuropathic pain, co-injection of morphine plus...
BC Week In Review | Jul 27, 2015
Clinical News

ABX-1431: Phase Ia started

Abide began a double-blind, placebo-controlled, Belgian Phase Ia trial to evaluate single and multiple ascending doses of ABX-1431 in about 60 healthy volunteers. Abide said potential indications include neuropathic pain, neuro-inflammation, neurodegenerative diseases and forms...
Items per page:
1 - 10 of 10